Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
JW Therapeutics is a leading clinical-stage cell therapy company in China, founded as a joint venture between Juno Therapeutics and WuXi AppTec. The company focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for patients with hematologic malignancies and solid tumors. Its lead product, Relmacabtagene autoleucel (Cartevaire), was the first CAR-T therapy to be approved as a Category 1 biologics product in China. JW Therapeutics operates an integrated platform that encompasses R&D, clinical development, and a state-of-the-art GMP manufacturing facility in Suzhou.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on JWTCR001 program sponsor in China.